Atsuo Maekawa

Atsuo Maekawa

Auto-generated profile, based on publicly available information

Atsuo Maekawa

Department of Cardiac Surgery, Fujita Health University School of Medicine, Toyoake 470-1192, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
TLToshiaki Lto
Toshiaki Lto
HHHiroaki Hagiwara
Hiroaki Hagiwara
AMAtsuo Maekawa
Atsuo Maekawa

6 May 2022 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
RHRyosuke Hayashi
Ryosuke Hayashi
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
KAKentaro Amano
Kentaro Amano
YSYusuke Sakurai
Yusuke Sakurai
YTYasushi Takagi
Yasushi Takagi
Patients with cardiovascular disease are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Although SARS-CoV2 vaccination may be effective, its impact on surgical patients is not well studied. We investigated the effects of cardiovascular surgery, especially under cardiopulmonary bypass (CPB), on the antibody titres after SARS-CoV2 vaccination. A prospective observational study was designed for patients undergoing surgery between July and November 2021. The immunoglobulin G against the receptor-binding domain was measured and antibody preserved rate (APR) was calculated from perioperative titres comparison. Enrolled 63 study patients were divided into 39 undergoing surgery with CPB (Group CPB) and 24 without CPB (Group None). Preoperative vaccines were BNT162b2 (Pfizer/BioNTech) (n = 58, 92%) and mRNA-1273 (Moderna) (n = 5, 8%). While immunoglobulin G against the receptor-binding domain titres did not significantly decrease after surgery in Group None, they decreased significantly in Group CPB from 21.80 [11.15, 37.85] to 11.95 [6.80, 18.18] U/ml (P < 0.001) a day after surgery, 11.40 [7.85, 22.65] U/ml (P < 0.001) 14 days after surgery and 7.60 [4.80, 17.60] U/ml (P < 0.001) a month after surgery. The APRs a day after the surgery were significantly lower in Group CPB (0.46 [0.41, 0.60]) than in Group None (0.80 [0.68, 0.87]) (P < 0.001). The SARS-CoV2 antibody titres significantly decreased with lower APRs immediately after surgery under CPB. Based on our informative results, careful considerations of vaccination schedule might be required for surgery under CPB.

4 October 2021 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
AMAtsuo Maekawa
Atsuo Maekawa
YTYoshiyuki Takami
Yoshiyuki Takami
KYKoji Yamana
Koji Yamana
KAKiyotoshi Akita
Kiyotoshi Akita
KAKentaro Amano
Kentaro Amano
YTYasushi Takagi
Yasushi Takagi

16 April 2022 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
KYKoji Yamana
Koji Yamana
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
YNYoshinori Nakahara
Yoshinori Nakahara
TKTakeyuki Kanemura
Takeyuki Kanemura
AMAtsuo Maekawa
Atsuo Maekawa
YTYasushi Takagi
Yasushi Takagi

2 February 2021 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
STShin-Ichi Tanida
Shin-Ichi Tanida
NHNaoki Hoshino
Naoki Hoshino
YSYusuke Sakurai
Yusuke Sakurai
KAKentaro Amano
Kentaro Amano
YTYasushi Takagi
Yasushi Takagi
We report wound management using a vacuum-assisted closure (VAC) system for the cannula sites of extracorporeal biventricular assist devices (BiVADs) for 295 days in a 23-year old Chinese female patient with fulminant giant cell myocarditis, who finally underwent heart transplantation. When the cannula sites appeared necrotic 3 months after BiVADs placement, she received negative pressure wound therapy prophylactically for four cannula sites, using a VAC system for 3 months, followed by no infections. Such prophylactic VAC therapy, using the skin barrier paste usually used for the ostomy pouching system to create a flatter surface and airtightness, may be useful to avoid cannula site infections, which is still a fatal complication causing sepsis, especially in patients with extracorporeal BiVADs.

Verified
Journal Article
Open access
PDF file
Yoshiyuki TakamiYoshiyuki Takami
Yoshiyuki Takami
AMAtsuo Maekawa
Atsuo Maekawa
KYKoji Yamana
Koji Yamana
KAKiyotoshi Akita
Kiyotoshi Akita
KAKentaro Amano
Kentaro Amano
YTYasushi Takagi
Yasushi Takagi
Fractional flow reserve (FFR) has been well validated as a modality for evaluating myocardial ischemia, demonstrating the superiority of FFR-guided percutaneous coronary intervention (PCI) over conventional angiography-guided PCI. As a result, the strategy for coronary artery bypass grafting (CABG) is shifting toward FFR guidance. However, the advantage of FFR-guided CABG over angiography-guided CABG remains unclear. While FFR-guided CABG can help avoid unnecessary grafting in cases of moderate stenosis, it may also carry the risk of incomplete revascularization. The limited use of FFR due to the need for hyperemia has led to the development of non-hyperemic pressure ratios (NHPRs). NHPR pullback provides trans-stenotic pressure gradients, which may offer valuable insights for CABG strategies. Recently, computed tomographic coronary angiography (CTCA) has emerged as a non-invasive modality that provides accurate data on lesion length, diameter, minimum lumen area, percentage stenosis, and the volume and distribution of high-risk plaques. With the introduction of FFR-CT, CTCA is now highly anticipated to provide both functional evaluation (of myocardial ischemia) via FFR-CT and anatomical information through serial quantitative assessment. Beyond the diagnostic phase, CTCA, augmented by automatic artificial intelligence, holds great potential for guiding therapeutic interventions in the future.